Publikationen, an denen er mitarbeitet Guillermo M. López Vivanco (10)

2023

  1. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

    New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513

2019

  1. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer

    Journal of Thoracic Oncology, Vol. 14, Núm. 2, pp. 304-310

2014

  1. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: The BRCA1-RAP80 Expression Customization (BREC) studies

    Annals of Oncology, Vol. 25, Núm. 11, pp. 2147-2155

2010

  1. Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients

    Lung Cancer, Vol. 68, Núm. 3, pp. 491-497

2009

  1. Screening for epidermal growth factor receptor mutations in lung cancer

    New England Journal of Medicine, Vol. 361, Núm. 10, pp. 958-967

2007

  1. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer

    Journal of Clinical Oncology, Vol. 25, Núm. 19, pp. 2747-2754

2006

  1. The place of targeted therapies in the management of non-small cell bronchial carcinoma: Molecular markers as predictors of tumor response and survival in lung cancer

    Revue des Maladies Respiratoires, Vol. 23, Núm. 5 C3

2004

  1. Single nucleotide polymorphisms and outcome in docetaxel - Cisplatin-treated advanced non-small-cell lung cancer

    Annals of Oncology, Vol. 15, Núm. 8, pp. 1194-1203

2003

  1. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group phase III randomized trial

    Journal of Clinical Oncology, Vol. 21, Núm. 17, pp. 3207-3213

  2. Influence of genetic markers on survival in non-small cell lung cancer

    Drugs of Today, Vol. 39, Núm. 10, pp. 775-786